- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
回复 HBVCURER 的帖子
OCB-030 is an orally available, sangamide-based, second generation cyclophilin inhibitor with a well-differentiated preclinical profile when compared to other cyclophilin inhibitors. Data presented in April at The International Liver Congress™ 2014, the annual meeting of the European Association for the Study of the Liver (EASL), indicated that OCB-030 may inhibit the hepatitis B virus by two mechanisms in vitro. First, the data indicated that OCB-030 directly inhibits several stages of viral replication in liver cells. Second, the data indicated that OCB-030 may act indirectly by strengthening the host immune response via IRFs, including potent inhibition of an interaction between cyclophilin A and IRF9, a key component of the Jak/Stat pathway. Data also indicated that the risk of developing resistance, a significant clinical problem with current therapies for hepatitis B, is very low with OCB-030.
OCB-030是一种口服用,sangamide为主,第二代环素抑制剂与分化良好的临床前轮廓相对于其他亲环蛋白抑制剂。在国际肝病会议™2014年,欧洲协会为肝脏(EASL)的研究年会上介绍了4月份的数据,表明OCB-030可通过体外两种机制抑制乙肝病毒。首先,数据表明,OCB-030直接抑制病毒复制的数个阶段中的肝细胞。第二,该数据表明,OCB-030可间接通过加强通过脉冲响应函数的宿主免疫反应,包括亲环素A和IRF9的JAK / STAT途径的一个关键组成部分之间的相互作用的强效抑制起作用。数据还表明,显影性的危险,一显著临床问题与目前的治疗方法为乙型肝炎,是非常低的与OCB-030。
由于cyclophilin inhibito目标是宿主,副作用的危险因素.
"副作用没有夸张到不可接受的地步" - 一位专家告诉我这个, 希望你是对的. |
|